Platelet inhibition with tirofiban early during percutaneous coronary intervention: Dosing revisited

Catheterization and Cardiovascular Interventions

Volumn 56, Issue 4, 2002, Pages 474-477

  Lakkis, Nasser ^a,c   Lakiss, Nada ^b   Bobek, Jeremy ^a   Farmer, John ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b Centre Hospitalier Regional de Namur   (Belgium)

^c BEN TAUB GENERAL HOSPITAL   (United States)

Author keywords

PCI; Platelet inhibition; Tirofiban

Indexed keywords

ACETYLSALICYLIC ACID; CITRIC ACID; CLOPIDOGREL; EDETIC ACID; HEPARIN; TIROFIBAN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CORONARY STENT; DOSE RESPONSE; FEMALE; HEART CATHETERIZATION; HEART MUSCLE ISCHEMIA; HUMAN; MALE; THROMBOCYTE FUNCTION;

CORONARY DISEASE; FEMALE; HEART CATHETERIZATION; HUMANS; MALE; MIDDLE AGED; PLATELET AGGREGATION INHIBITORS; PLATELET FUNCTION TESTS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; RADIOLOGY, INTERVENTIONAL; TYROSINE;

EID: 0036316139     PISSN: 15221946     EISSN: None     Source Type: Journal    
DOI: 10.1002/ccd.10238     Document Type: Article

References (21)

1. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty
2. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization
3. Randomized placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein IIb/IIIa blockade
4. Novel dosing regimen of eptifibatide in planned coronary stent implantation: A randomised, placebo-controlled trial
5. Effects of platelet glycoprotein IIb/IIIa blockade on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty
6. Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization
7. Point-of-care measured platelet inhibition correlates with a reduced risk of an adverse cardiac event after percutaneous coronary intervention: Results of the GOLD (AU-Assessing Ultegra) multicenter study
8. Antiplatelet effects of abciximab, tirofiban, and eptifibatide in patients undergoing coronary stenting
9. A comparative study of light transmission aggregometry and automated bedside platelet function assays in patients undergoing percutaneous coronary intervention and receiving abciximab, eptifibatide, or tirofiban
10. The rapid platelet function assay: An automated and quantitative cartridge-based method
11. Use of ICHOR-platelet works to assess platelet function in patients treated with GPIIb/IIIa inhibitors
12. Preclinical development of 7E3 Fab: Mouse/human chimeric antibody fragment that inhibits platelet function by blockade of GPIIb/IIIa receptors with observations on immunogenicity of C7E3 Fab in humans
13. Randomized placebo-controlled trial of effect of eptifibatide on complications of percutaneous intervention: IMPACT II
14. Differential inhibition of platelet aggregation induced by adenosine diphosphate or a thrombin-receptor activating peptide in patients treated with bolus chimeric 7E3 Fab: Implications for the inhibition of the internal pool of GPIIb/IIIa receptors
15. The interaction of extacellular calcium with the platelet membrane glycoprotein IIb/IIIa complex
16. Effect of calcium on GP IIb/IIIa interactions with integrilin: Enhanced GPIIb/IIIa binding and inhibition of platelet aggregation by reductions in the concentration of ionized calcium in plasma anticoagulated with citrate
17. Effect of Ca-chelation on the platelet inhibitory ability of the GPIIb/IIIa antagonists abciximab, eptifibatide and tirofiban
18. Monitoring antiplatelet therapy: What is the best method?
19. In-vitro dose response to different GPIIb/IIIa antagonists: Interlaboratory comparison of various platelet function tests
20. The platelet receptor inhibition in ischemic syndrome management in patients limited by unstable signs and symptoms: Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q wave myocardial infarction
21. Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban